Marker Therapeutics, Inc.
MRKR
$1.10
-$0.10-8.33%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 647.67% | 53.30% | 0.79% | 39.18% | -74.23% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 647.67% | 53.30% | 0.79% | 39.18% | -74.23% |
| Cost of Revenue | 69.74% | -1.79% | -23.74% | 19.93% | -43.07% |
| Gross Profit | 13.55% | 27.80% | 37.87% | -9.68% | 31.05% |
| SG&A Expenses | -39.50% | -54.66% | -43.80% | -14.76% | -56.32% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.11% | -28.99% | -31.58% | 5.17% | -49.35% |
| Operating Income | 25.00% | 44.17% | 40.85% | 3.32% | 45.08% |
| Income Before Tax | 22.60% | 46.51% | 43.36% | 10.08% | 47.93% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 22.60% | 46.51% | 43.36% | 9.97% | 47.93% |
| Earnings from Discontinued Operations | -- | -- | -- | 92.26% | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 22.60% | -187.16% | 51.83% | 27.31% | 56.91% |
| EBIT | 25.00% | 44.17% | 40.85% | 3.32% | 45.08% |
| EBITDA | -- | -- | -- | -0.67% | 50.01% |
| EPS Basic | 23.44% | -186.01% | 52.81% | 31.53% | 59.18% |
| Normalized Basic EPS | 23.44% | 47.22% | 44.52% | 11.99% | 50.67% |
| EPS Diluted | 23.53% | -188.72% | 52.60% | 31.53% | 59.17% |
| Normalized Diluted EPS | 23.44% | 47.22% | 44.52% | 11.99% | 50.67% |
| Average Basic Shares Outstanding | 1.10% | 1.35% | 2.08% | 6.17% | 5.57% |
| Average Diluted Shares Outstanding | 1.10% | 1.35% | 2.08% | 6.17% | 5.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
